# Hepatitis B

Use triple-panel serology to identify infection, immunity, and reactivation risk; stage confirmed chronic infection with HBV DNA, liver assessment, and fibrosis testing; then select durable antiviral suppression, pregnancy prevention measures, or surveillance based on cirrhosis and host risk.

**Clinical question:** How should physicians diagnose, stage, treat, and monitor acute and chronic hepatitis B infection?

Updated: 2026-08-24T16:40:12.307192+00:00

## What matters in practice
- Screen adults at least once with HBsAg, total anti-HBc, and anti-HBs; screen HBsAg during every pregnancy.[1][18][23]
- HBsAg positivity with IgM anti-HBc indicates acute infection, whereas HBsAg positivity with total anti-HBc positivity and IgM anti-HBc negativity indicates chronic infection.[18]
- At chronic HBV entry to care, obtain quantitative HBV DNA, HBeAg/anti-HBe, CBC, liver chemistries, synthetic-function tests, viral coinfection testing, abdominal ultrasound, and fibrosis assessment.[23]
- For patients requiring therapy, entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide are preferred high-barrier nucleos(t)ide analogues.[9][14][17][24]
- Cirrhosis changes urgency: use nucleos(t)ide analogue therapy rather than pegylated interferon in decompensated disease, assess transplant eligibility, and continue HCC surveillance despite viral suppression.[24]
- An isolated anti-HBc result requires interpretation for waned resolved infection, occult HBV, false positivity, or passive maternal antibody; management differs by context and immunosuppression exposure.[18]

## Screen with a triple panel and act on the serologic pattern

Use HBsAg, total anti-HBc, and anti-HBs as the initial adult screening panel.

Screen all adults aged 18 years or older at least once with HBsAg, total anti-HBc, and anti-HBs. Test HBsAg during each pregnancy. A positive HBsAg identifies current infection but does not distinguish acute from chronic disease; order IgM anti-HBc when current infection is identified or clinically suspected.[1][18][23]

Interpret HBsAg positive, total anti-HBc positive, IgM anti-HBc positive, and anti-HBs negative as acute HBV infection. HBsAg positive, total anti-HBc positive, IgM anti-HBc negative, and anti-HBs negative indicates chronic HBV infection; link either pattern to hepatitis B care rather than treating serology alone as proof of disease activity.[18]

Interpret HBsAg negative, total anti-HBc positive, and anti-HBs positive as resolved infection. Counsel these patients that prior HBV exposure creates reactivation risk, particularly before immunosuppressive therapy. HBsAg negative, total anti-HBc negative, and anti-HBs negative indicates susceptibility when prior completion of a vaccine series is not documented; offer hepatitis B vaccination.[1][18]
- Order IgM anti-HBc to distinguish acute or recently acquired HBV from chronic infection when HBsAg and total anti-HBc are positive.[18][21]
- Do not diagnose vaccine-derived immunity from anti-HBs alone if a complete vaccine series is undocumented; complete vaccination when indicated.[18]

### Isolated anti-HBc requires a context-specific next test

For HBsAg-negative, total anti-HBc-positive, anti-HBs-negative results, consider waned anti-HBs after resolved infection, occult HBV infection, false-positive anti-HBc, passive transfer to an infant born to an HBsAg-positive parent, or an HBsAg mutant not detected by the assay. Before immunosuppression, obtain the triple panel if chronic HBV is not already known and evaluate this pattern for occult infection or reactivation risk rather than assuming susceptibility.[18][23]

*HBV screening-pattern interpretation and immediate action.[18]*

| HBsAg | Total anti-HBc / IgM anti-HBc | Anti-HBs | Interpretation | Immediate action |
| --- | --- | --- | --- | --- |
| Positive | Total positive; IgM positive | Negative | Acute HBV infection.[18] | Link to hepatitis B care.[18] |
| Positive | Total positive; IgM negative | Negative | Chronic HBV infection.[18] | Stage virologic activity and liver disease.[23] |
| Negative | Total positive; IgM not required | Positive | Resolved infection.[18] | Document reactivation risk before immunosuppression.[18] |
| Negative | Total negative | Positive | Vaccine-derived immunity if a complete series is documented.[18] | Complete vaccine series if vaccination is not documented.[18] |
| Negative | Total positive | Negative | Isolated anti-HBc; possibilities include resolved infection with waned anti-HBs, occult HBV, false positivity, or passive antibody.[18] | Determine context; assess for occult infection or reactivation risk when relevant.[18][23] |
| Negative | Total negative | Negative | Susceptible if no documented completed vaccination series.[18] | Offer hepatitis B vaccination.[18] |

## Stage chronic HBV before deciding on antiviral therapy

Treatment decisions require viral replication, inflammatory activity, fibrosis stage, and cirrhosis status.

At the first chronic HBV visit, obtain quantitative HBV DNA and HBeAg/anti-HBe, then assess hepatic injury and reserve with CBC, ALT, AST, albumin, total bilirubin, alkaline phosphatase, and INR. Obtain HAV IgG to determine vaccination need; test HCV antibody with reflex HCV RNA if positive; test HDV antibody with reflex HDV RNA if positive. Perform abdominal ultrasound and fibrosis assessment with transient elastography or a serum fibrosis marker; individualize liver biopsy when noninvasive findings and the treatment decision remain discordant.[23]

Do not use an apparently normal aminotransferase value to exclude fibrosis. In chronic HBV, guideline-relevant ALT elevations may begin above 30 U/L in men and 19 U/L in women, and significant fibrosis can occur with normal liver enzymes. Use fibrosis staging to distinguish lower-risk infection from active or advanced liver disease requiring treatment consideration.[5]

Classify disease by HBeAg status, HBV DNA, ALT, and fibrosis rather than using a single measurement. HBeAg positivity or detectable HBV DNA indicates viral replication; anti-HBe generally corresponds to lower replication, but does not exclude HBeAg-negative chronic hepatitis. Repeated HBV DNA and ALT measurements are needed when activity is uncertain or treatment is deferred.[22][9][10]
- Use transient elastography or a validated serum fibrosis marker at baseline; reserve biopsy for an individualized question that noninvasive testing cannot resolve.[23]
- Calculate FIB-4 as age × AST divided by platelet count × square root of ALT; a reported advanced-fibrosis threshold is FIB-4 at least 3.25.[6]
- Evaluate every chronic HBV patient for clinical evidence of cirrhosis or HCC and obtain abdominal ultrasound as part of initial assessment.[23]

### Recognize the phase patterns that change follow-up intensity

HBeAg-positive patients with high HBV DNA but normal ALT and no advanced fibrosis may be in HBeAg-positive chronic infection, whereas elevated ALT or clinically important fibrosis supports HBeAg-positive chronic hepatitis. HBeAg-negative patients with normal ALT, low HBV DNA, and absent or mild fibrosis fit a lower-replicative pattern; elevated HBV DNA with biochemical or fibrotic disease supports HBeAg-negative chronic hepatitis.[6][9]

If treatment is deferred in immune-tolerant chronic HBV, measure ALT at least every 6 months to identify transition toward active hepatitis. In compensated cirrhosis with low-level viremia when treatment is not initiated, monitor HBV DNA and for decompensation every 3 to 6 months; begin therapy if HBV DNA rises or clinical decompensation occurs.[10][24]

*Baseline chronic HBV assessment organized by the decision it informs.[23][5][6]*

| Decision | Required assessment | Decision-changing interpretation |
| --- | --- | --- |
| Current replication | Quantitative HBV DNA; HBeAg and anti-HBe.[23] | High replication, particularly with elevated ALT or fibrosis, supports active chronic hepatitis and antiviral-treatment assessment.[9][22] |
| Inflammatory activity | Serial ALT and AST; consider ALT >30 U/L in men or >19 U/L in women clinically significant in chronic HBV.[5] | Normal ALT does not exclude significant fibrosis; integrate with fibrosis testing.[5] |
| Fibrosis or cirrhosis | Transient elastography or serum fibrosis marker; individualized biopsy when needed.[23] | FIB-4 ≥3.25 is a reported advanced-fibrosis threshold.[6] |
| Coinfection and preventive needs | HAV IgG; HCV antibody with HCV RNA if positive; HDV antibody with HDV RNA if positive.[23] | Coinfection or absent HAV immunity changes disease management or vaccination planning.[23] |
| Structural disease | Abdominal ultrasound.[23] | Evaluate for cirrhosis or HCC at entry to care.[23] |

## Use high-barrier nucleos(t)ide analogues for patients with active or advanced disease

Treat cirrhosis and patients with high HBV DNA plus active or advanced liver disease.

Antiviral therapy is recommended for patients with cirrhosis or with high HBV DNA plus active or advanced liver disease. The practical treatment goal is durable HBV replication suppression to prevent disease progression and HCC; sustained HBsAg loss is the optimal endpoint but is not the usual immediate endpoint of nucleos(t)ide analogue therapy.[4][9]

For treatment-naive chronic HBV requiring therapy, choose a high-resistance-barrier agent: entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide. Tenofovir and entecavir are preferred because of potency and minimal resistance risk; avoid low-genetic-barrier antivirals when resistance could precipitate decompensation.[9][14][17][24]

Pegylated interferon alfa can be considered in selected patients with mild to moderate chronic hepatitis B who can tolerate an interferon-based finite course. Do not use pegylated interferon in decompensated cirrhosis; nucleos(t)ide analogues are safer in cirrhosis, and transplant evaluation should proceed concurrently for eligible patients with decompensation.[9][24]
- Avoid entecavir as the preferred option when there is prior lamivudine resistance.[24]
- Avoid pegylated interferon in autoimmune disease, uncontrolled psychiatric illness, cytopenias, severe cardiac disease, uncontrolled seizures, and decompensated cirrhosis.[24]
- Do not routinely combine antiviral agents solely to improve chronic HBV suppression; combination therapy is generally not recommended.[9]

### Cirrhosis and HIV override routine treatment deferral

In decompensated cirrhosis, start a nucleos(t)ide analogue and assess transplant eligibility; pegylated interferon is contraindicated. Monitor clinical status and laboratory values closely because advanced decompensation increases vulnerability to adverse outcomes, including reported lactic acidosis with some nucleos(t)ide analogues.[24]

For HIV with chronic HBV, use an antiretroviral regimen containing TDF or TAF plus either lamivudine or emtricitabine, regardless of HBV DNA level. Do not manage HBV in HIV as a separate monotherapy decision when antiretroviral regimen composition can expose HBV to inadequate activity.[23]

*Chronic HBV treatment selection by clinical setting.[9][14][23][24]*

| Clinical setting | Preferred approach | Avoid or add |
| --- | --- | --- |
| Treatment-naive chronic HBV requiring therapy | Entecavir, TDF, or TAF.[9][14][17][24] | Avoid low-resistance-barrier antiviral monotherapy.[24] |
| Compensated cirrhosis | High-barrier nucleos(t)ide analogue; continued monitoring for disease progression and HCC.[24] | Pegylated interferon is not contraindicated but nucleos(t)ide analogues are safer.[24] |
| Decompensated cirrhosis | Nucleos(t)ide analogue and concurrent transplant evaluation if eligible.[24] | Do not use pegylated interferon.[24] |
| Prior lamivudine resistance | Select therapy other than entecavir as the preferred agent.[24] | Account for prior resistance when choosing antiviral therapy.[24] |
| HIV and chronic HBV | TDF or TAF plus 3TC or FTC within ART.[23] | Treat regardless of HBV DNA level.[23] |

## Continue surveillance and prevent transmission despite virologic suppression

Suppression reduces progression risk but does not remove the need for longitudinal liver care.

Monitor treated patients for treatment response and adherence, and continue HCC surveillance because antiviral therapy does not eliminate HCC risk. Monitor untreated patients according to their phase and fibrosis risk; at minimum, immune-tolerant adults need ALT testing every 6 months, while compensated cirrhosis with untreated low-level viremia requires HBV DNA and decompensation assessment every 3 to 6 months.[9][10][24]

For patients with resolved infection, document anti-HBc positivity and counsel regarding HBV reactivation before future chemotherapy or immunosuppressive therapy. In people with HIV who will receive immunosuppressive therapy, perform triple-panel HBV screening before treatment unless chronic HBV is already known.[18][23]

Vaccination prevents chronic carriage and liver cancer at the population level. In Taiwan, universal infant vaccination reduced childhood HBsAg carriage from 10% to less than 1% over 10 years, and childhood HCC incidence declined 6 to 10 years after program initiation. Offer vaccination to susceptible patients identified by triple-panel testing.[7][18]
- Continue HCC surveillance after antiviral initiation; viral suppression does not eliminate risk.[24]
- Vaccinate patients with HBsAg negative, total anti-HBc negative, and anti-HBs negative serology when no completed series is documented.[18]
- For HBsAg-negative, anti-HBc-positive patients, flag reactivation risk in the medical record before immunosuppression.[18]

### Pregnancy requires repeated screening and postpartum follow-up

Test HBsAg during every pregnancy. In pregnant patients with chronic HBV, monitor frequently during pregnancy and through 6 months postpartum so antiviral therapy can be initiated when indicated and postpartum disease activity is detected.[1][16]

*Monitoring and prevention actions by HBV status.[10][16][18][24]*

| Status or setting | Action | Timing |
| --- | --- | --- |
| Immune-tolerant chronic HBV without treatment | Check ALT for transition to active disease.[10] | At least every 6 months.[10] |
| Compensated cirrhosis with low-level viremia when treatment is not initiated | Assess HBV DNA and clinical decompensation; initiate treatment if either worsens.[24] | Every 3 to 6 months.[24] |
| On antiviral therapy | Monitor response and adherence; continue HCC surveillance.[9][24] | Longitudinally throughout treatment.[9][24] |
| Resolved HBV infection | Counsel on reactivation risk before immunosuppression.[18] | Before immunosuppressive therapy.[18] |
| Pregnancy with chronic HBV | Monitor disease activity and reassess postpartum.[16] | During pregnancy and up to 6 months postpartum.[16] |
| Susceptible serology | Offer hepatitis B vaccine.[18] | At identification of susceptibility.[18] |

## References
1. Potential Hepatitis B Virus (HBV) Device Reclassification — www.fda.gov — https://www.fda.gov/media/172296/download
2. IMMULITE - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/cdrh_docs/pdf/P010053c.pdf
3. Clinical outcomes of untreated adults living with chronic ... — www.thelancet.com — https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00226-7/fulltext
4. Hepatitis B — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01468-4/fulltext
5. Guidelines on the management of abnormal liver blood tests — gut.bmj.com — https://gut.bmj.com/content/67/1/6
6. EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection | Gut — gut.bmj.com — https://gut.bmj.com/content/early/2025/10/27/gutjnl-2025-335449
7. Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children | New England Journal of Medicine — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199706263362602
8. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0168827825001746
9. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0168827812001675
10. AASLD guidelines for treatment of chronic hepatitis B — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/hep.28156
11. Hepatitis B Virus Genotype B - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/hepatitis-b-virus-genotype-b
12. Update on prevention, diagnosis, and treatment of chronic ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/hep.29800
13. ALEH position statement on the management of hepatitis B virus infection 2025 — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S166526812600013X
14. AASLD 2018 Hepatitis B Guidance — aasldpubs.onlinelibrary.wiley.com — https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.29800
15. Chronic Hepatitis B Infection: Patient Guidance — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jgh.70177
16. Management of chronic hepatitis B during pregnancy — academic.oup.com — https://academic.oup.com/gastro/article/6/4/257/5057986
17. Hepatitis B | Red Book — publications.aap.org — https://publications.aap.org/redbook/book/347/chapter/5752538/Hepatitis-B
18. Clinical Testing and Diagnosis for Hepatitis B | Hepatitis B | CDC — www.cdc.gov — https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html
19. Seroprevalence of Hepatitis B Surface Antigen (HBsAg) ... — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/10940/cdc_10940_DS9.pdf
20. Hepatitis B Surveillance Guidance — www.cdc.gov — https://www.cdc.gov/hepatitis/php/surveillance-guidance/hepatitis-b.html
21. Sexually Transmitted Diseases Treatment Guidelines, 2015 — www.cdc.gov — https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm
22. Recommendations for Identification and Public 
Health Management of Persons with Chronic Hepatitis B Virus Infection — www.cdc.gov — https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm
23. Hepatitis B Virus Infection: Adult and Adolescent OIs | NIH — clinicalinfo.hiv.gov — https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/hepatitis-b-virus
24. AASLD Guidelines for Treatment of Chronic Hepatitis B - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5987259

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.